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ABSTRACT
We investigated the effects of the antioxidant N-acetylcysteine (NAC) on early outcomes
of deceased donor renal transplantation. Between April 2005 and June 2008, adult primary
graft recipients of deceased renal donors were assigned to treatment (n  38) or control
(n  36) groups and evaluated for 90 days and one year after renal transplantation. The
treatment group received NAC orally (600 mg twice daily) from day 0 to 7 postoperatively.
Renal function was determined by serum creatinine, MDRD and Cockcroft-Gault
estimated GFR (eGFR), delayed graft function (DGF) and dialysis free Kaplan-Meier
estimate curve. Serum levels of thiobarbituric acid reactive substances (TBARS), were
employed as markers of oxidative stress. The NAC group displayed a lower mean serum
creatinine during the first 90 days (P  .026) and at 1 year after transplantation
(P  .005). Furthermore, the NAC group showed a higher mean eGFR throughout the
first 90 days and at 1 year. DGF was lower among the NAC group (P  .017) and these
recipients required fewer days of dialysis (P  .012). Oxidative stress was significantly
attenuated with NAC (P  .001). Our results suggested that NAC enhanced early
outcomes of deceased donor renal transplantation by attenuating oxidative stress.
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NDECEASED DONOR RENAL TRANSPLANTA-TION represent over 60% of grafts in the United
States and over 50% in Brazil.1 The need for deceased
onor grafts is increasing due to the relative shortage of
iving donors. However, the survival rate of deceased donor
rafts is lower than those of related or unrelated living
onors,2 a difference that is not fully explained by better
human leukocyte antigen (HLA) matching,3 less recipient
ensitization,4 or shorter cold ischemia times2 alone.
Despite experience in deceased donor kidney transplan-
tations, Brazilian transplantation centers have reported
rates of delayed graft function (DGF) that exceed 60%.1 In
contrast, high-volume centers in the United States and in
Europe report rates from 20% to 50%.5 Among the possi-
ble reasons for this apparent discrepancy are the long
waiting list time, poor recipient condition, less than ideal
care of deceased donors, use of EuroCollins instead of
Belzer preservation solution, and long cold ischemia times.1
Reactive oxygen metabolites are believed to be important
mediators of various forms of acute kidney injury, such as
ischemic renal failure6 and radiocontrast nephrotoxicity.7
We hypothesized that the above-mentioned adverse condi-
tions associated with deceased donor kidney transplanta-
tion cause oxidative stress that could be mitigated by
© 2011 by Elsevier Inc. All rights reserved.
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Transplantation Proceedings, 43, 1443–1449 (2011)reatment with N-acetylcysteine (NAC), a potent antioxi-
ant that scavenges free radicals,8 seeking to reduce the
GF rate, with the necessity of posttransplant dialysis by
mproving early graft function. Therefore, attenuation of
xidative stress generated in the renal transplant undergo-
ng ischemia-reperfusion processes represent an attractive
herapeutic target.9
Previous studies from our laboratory showed that NAC
administration attenuates kidney injury in animals submit-
ted to a renal ischemia-reperfusion model.10,11 Other inves-
igators have also experimentally demonstrated a protective
ole of NAC for kidneys subjected to ischemia-reperfusion
njury.12–16 However, little is known about the effects of
AC in clinical kidney transplantation. Treatment with
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1444 DANILOVIC, LUCON, SROUGI ET ALNAC in stable renal transplant recipients has shown a
positive influence on renal function,17 but the role of NAC
or other antioxidants on early stages of deceased renal
transplantation is less known. The aim of this study was to
investigate the therapeutic effects of NAC on early out-
comes of deceased donor renal transplantations in relation
to oxidative stress.
MATERIALS AND METHODS
We performed an institutional review board approved study
(CAPPesq 076/05), in accordance with the Helsinki Declaration, by
prospectively randomizing recipients of a single Brazilian kidney
transplantation center. We compared the use of oral NAC (dose of
600 mg twice daily) from days 0 to 7 postoperatively among
consecutive recipients older than 18 years of age of primary
kidney-only grafts from deceased donors. Between April 2005 and
June 2008, we randomly assigned 74 adult recipients to NAC
treatment or control groups following a previously generated
randomization list. Written informed consent was provided to all
patients. Investigators and outcome assessors were blinded to the
assignments.
All deceased multiorgan donors were heart-beating as defined by
conventional brain-death criteria. EuroCollins was the routinely
used kidney cold storage solution. Recipients were selected for
donor organs by a computer program at the government depart-
ment for organ transplant management on the basis of HLA
matching. The algorithm gives 3, 2, and 0.5 points for each
compatibility among DR, B, and A locí, respectively. The waiting
time was considered only for those patients with an identical HLA
score.1
Preoperatively administered induction immunosuppressive ther-
apy used anti-interleukin (IL)-2 receptor monoclonal antibodies
and the maintenance regimen was based on tacrolimus, mycophe-
nolate, and prednisone.
The primary outcome measure was oxidative stress assessed by
serum levels of thiobarbituric acid reactive substances (TBARS).18
Blood samples were collected every morning from the immediate
preoperative day (before immunosuppression therapy) to day 7
postoperative. TBARS serum levels were determined by diluting a
0.2-mL serum sample in 0.8 mL of distilled water, to which 1 mL of
17.5% trichloroacetic acid (99% PA ACS Sigma) was immediately
added and subsequently, 1 mL of 0.6% thiobarbituric acid (pH 2).
The sample was then placed in a boiling water bath for 15 minutes.
After cooling, 1 mL of 70% trichloroacetic acid was added before
the mixture was incubated for 20 minutes. The sample was then
centrifuged for 15 minutes at 2000 rpm. Using a spectrophotome-
ter, the optical density of the supernate was read at 534 nm against
a reagent blank. The concentration of lipid peroxidation products
was calculated as TBARS-equivalents using a molar extinction
coefficient of 1.56  105 mol/cm. Serum levels of TBARS are
xpressed as nmol/mL.
The secondary study endpoints were the renal graft function
s assessed by serum creatinine levels, MDRD (Modification of
iet in Renal Disease) formula,19 and Cockcroft-Gault20 esti-
mated glomerular filtration rate (eGFR) at postoperative days 7,
15, 30, 60, and 90 as well as 1 at year post-transplantation. In
addition, we evaluated the dialysis-free Kaplan-Meier estimate
curve for the length of delayed graft function (DGF), which was
defined as the need for dialysis beginning during the first week
posttransplantation except when caused by hypervolemia.Acute rejection episodes were biopsy-proven using Doppler
ultrasound a graft biopsy was performed in anuric or oliguric
recipients who had not demonstrated surgical complications or
displayed a rising creatinine during follow-up.
Statistical analysis was performed using SPSS 16.0. (SPSS Inc, Ill,
USA). The results are expressed as mean values  standard
deviations for continuous variables. Comparisons used the 2 test
or Fisher test for categorical data and Student t test for normally
distributed continuous data. For parameters without a Gaussian
distribution, we employed the Mann-Whitney U test, and the
Wilcoxon test for comparisons of two paired groups.
Serial serum TBARS concentrations, serum creatinine values,
and estimated creatinine clearances were compared within and
between groups using repeated-measures analysis of variance using
SAS version 8.02. The determination of recipients with no need for
dialysis was evaluated using a Kaplan-Meier analysis with compar-
ison using the log-rank test. Probability values .05 were regarded
as statistically significant.
RESULTS
Pretransplant demographic and clinical donor characteris-
tics (Table 1) and recipient features (Table 2) revealed no
significant differences between the groups. Both groups
showed equivalent pretransplant mean levels of TBARS.
NAC administration through the first 7 days after deceased
donor kidney transplantation resulted in attenuation of
oxidative stress as measured by mean TBARS levels (P 
.001; Fig 1). The power of the study for TBARS analysis was
0.975.
Throughout the first 90 days after transplantation, the
control group displayed higher mean serum creatinine
values compared with the NAC group (P  .026; Fig 2).
Throughout the study the mean eGFR calculated by the
MDRD and by the Cockcroft-Gault formula was greater for
recipients in the NAC than the control group according to
the analysis of variance model (P  .005; Fig 3, and P 
0.029, Fig 4 respectively). One year after deceased donor
kidney transplantation, the mean  standard deviation
creatinine value remained lower in the NAC than the
control group (1.354  0.478 mg/dL vs 1.743  0.526; P 
.005). In addition the mean values  standard deviation of
Table 1. Demographic and Clinical Donor Characteristics
Features
Control
(n  36)
NAC
(n  38) P
Sex (% male) 55.6 44.7 .352
Race (Caucasian/non-
Caucasian)
23/13 24/14 .771
Age (years, mean  SD) 50.2  11.5 49.2  11.1 .698
BMI (kg/m2, mean  SD) 25.7  3.2 26.4  3.2 .341
xtended criteria (%) 36.1 34.2 .864
ays of ICU (n,
mean  SD)
7.6  6.0 5.5  4.7 .118
iabetes mellitus (%) 5.6 10.5 .661
ypertension (%) 38.9 39.5 .959
reatinine (mg/dL,
mean  SD)
1.4  0.7 1.4  0.9 .976BMI, body mass index; ICU, intensive care unit; NAC, N-acetylcysteine; SD,
standard deviation.
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PROTECTIVE EFFECT OF N-ACETYLCYSTEINE 1445MDRD and Cockcroft-Gault-estimated creatinine clear-
ances were higher among NAC than the control group;
62.45  23.03 versus 49.13  13.28 (P  .015) and 63.68 
23.40 versus 49.16  13.12 mL/min (P  .020), respectively.
The rate of DGF was lower among NAC than control
recipients: 21/38 (55.3%) versus 26/36 (72.2%; P  .017).
igure 5 shows an additional advantage of the NAC group
egarding the need for dialysis after deceased renal trans-
lant (P  .012).
During the first year after transplantation biopsy-proven
cute rejection was diagnosed in 10 control (10/36, 27.8%)
nd eight NAC recipients (8/38, 21.1%; P  .50).
One-year graft and patient survivals were similar between
groups; control 32/36 (88.9%) versus NAC 31/38 (81.6%;
P  .377), and 32/36 (88.9%) versus NAC 32/38 (84.2%;
P  .556), respectively.
DISCUSSION
Oxidative stress seems to play a major role in the detrimen-
tal effects of ischemia and reperfusion processes.21 Our
study suggested that NAC administration to transplant
recipients of deceased donor kidneys during the first week
after transplantation promotes a faster, sustained recovery
Table 2. Demographic and Clinical Recipient Characteristics
Features
Control
(n  36)
NAC
(n  38) P
Sex (male, %) 55.6 34.2 .065
Race (African-
American/non-
African-
American)
12/24 12/26 .872
ge (years,
mean  SD)
48.8  11.1 50.7  11.8 .479
MI (kg/m2,
mean  SD)
25.1  4.4 25.3  4.7 .825
Cause of ESRD (%) .163
Glomerulosclerosis 50.0 42.1
Diabetic
nephropathy
19.4 15.8
Glomerulonephritis 16.7 5.2
ADPKD 5.6 18.4
Others 8.4 18.4
Dialysis time (mo,
mean  SD)
52.6  39.1 58.5  47.8 .854
PRA (%) .608
0 66.7 76.3
1–50 19.4 15.8
50 13.9 7.9
LA mismatch
(mean  SD)
3.3  1.4 2.9  1.4 .280
dentical DR (%) 50.0 44.7 .583
old ischemia (h,
mean  SD)
22.8  7.5 25.1  5.4 .130
BMI, body mass index; ESRD, end-stage renal disease; ADPKD, autosomal-
dominant polycystic kidney disease; PRA, panel-reactive antibody; HLA, hu-
man leukocyte antigen; SD, standard deviation.of graft function by attenuating oxidative stress.Reactive oxygen species (ROS) are produced primarily
y mitochondria as a by-product of normal metabolism
uring the conversion of molecular oxygen to water.22 Cells
ave several antioxidant defense mechanisms, such as su-
eroxide dysmutase23 and glutathione.8 Oxidative stress is
enerated when an imbalance exists between oxidants and
ntioxidants. ROS serve as mediators of a variety of signal
ransduction pathways and gene expressions; however, ROS
xcess may damage cellular macromolecules with oxidation
f DNA.24
Loss of the antioxidant capacity of a cell is mainly caused
by a decrease in glutathione and/or its precursor cysteine,
because glutathione is the most abundant intracellular free
thiol. Therefore, NAC, which is a precursor of L-cysteine
and reduced glutathione, has extensively been studied as an
antioxidant.8 NAC is a source of sulfydryl groups in cells
and a scavenger of free radicals, such as hydroxyl radicals
and hydrogen peroxide. In addition, NAC can triple endo-
thelial nitric oxide synthase expression as well as increase
nitric oxide bioavailability.25 Thus, attenuation of oxidative
stress may explain the superior early graft function.
We chose the oral route for NAC administration, be-
cause it has proved to be safer and as effective as the
intravenous route.26 In fact, no side effects were detected in
the present study. We employed an oral NAC dose of 600
mg twice daily based on a previous study by Tepel et al, who
demonstrated a reduction in cardiovascular events among
patients with end-stage renal failure taking this dose of
NAC.27
ROS are unstable compounds, with half-live of seconds;
thus, indirect methods have been developed to measure
lipoperoxidation products such as TBARS.8 A severe per-
xidative state exists in patients with end-stage renal dis-
ase, as assessed by high TBARS levels, which can be
own-regulated by NAC administration.28
Several studies have demonstrated beneficial effects of
NAC on the pathogenesis of several acute renal illnesses,
including ischemic and reperfusion injury.7,10,11,29 NAC pro-
ects renal function in models of ischemia and reperfusion
njury, reducing renal interstitial inflammation.11,13 These
ffects are associated with increased renal glutathione levels,
uggesting that NAC attenuates renal oxidative stress.13
Few clinical trials have addressed the effects of NAC in
transplant recipients. Intraoperative NAC administration
during the anhepatic phase of liver transplantation signifi-
cantly increased recipient IL-4 plasma levels before and
after reperfusion as well as IL-10 before reperfusion. The
changes were associated with protective effects against
reperfusion injury.30 Moreover, NAC treatment in patients
ith stable renal function after transplantation increases
igh-density lipoprotein cholesterol and antioxidant mole-
ules in relation to glutathione peroxidase, with a positive
nfluence on renal function.17
We assessed the effects of the antioxidant NAC on the
early graft function of deceased donor renal transplanta-
tions. NAC was administered during the first week after
transplantation because other investigators have suggested
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1446 DANILOVIC, LUCON, SROUGI ET ALthat attenuation of oxidative stress generated in the peri-
reperfusion period may prevent lipid peroxidation and
vasculopathy.21
Our study showed that the administration of NAC
during the first 7 days after deceased donor kidney
transplantation caused down-regulation of TBARS levels
(P  .001). Until the third day after transplantation,
TBARS levels increased in both groups, probably due to
excessive generation of ROS that overcame NAC antiox-
idant effects. However, after the third day, TBARS levels
were progressively reduced among the NAC group, while
they were increased among controls. These results sug-
gest that oxidative stress generated during the ischemia
and reperfusion process peaks in the first 3 days after
reperfusion. Interventions to reduce oxidative stress
should be directed to this early period after transplanta-
tion and before reperfusion.
Oxidative stress modulation by antioxidant effects of
NAC showed positive impacts on early graft function.
Recipients who received NAC showed faster, sustained
allograft functional recovery. Throughout the first 90 days
of follow-up, mean serum creatinine curves decreased at a
faster rate in the NAC compared with the control group
(P  .026). In addition, the eGFR increased at a faster rate
Fig 1. TBARS (mean  standard
error of the mean) from recipients
of deceased kidney transplant
through the postoperative period.
The table shows a comparison of
TBARS (mean  standard devia-
ion) between groups. TBARS,
hiobarbituric acid reactive sub-
tances; PO, postoperative day;
AC, N-acetylcysteine; ANOVA,
nalysis of variance.in the NAC compared with the control group throughoutfollow-up. The beneficial effect on renal function continued
at 1 year after transplantation. Furthermore, the NAC
group showed a lower rate of DGF (P  .017), requiring
fewer days of dialysis (P .012). As a result, the immediate
orbidity of deceased donor renal transplant was signifi-
antly reduced.
The reported frequency of DGF among deceased donor
idney transplantations varies from 20% to 50% world-
ide.5 This incidence is lower than ours; our historical data
how a rate of more than 60%.1 It is believed that less than
deal care of deceased donors is one of the major factors
roducing this high incidence of DGF in addition to long
old ischemia times, a high proportion of patients of black
nd mixed ethnicity, relatively longer mean dialysis times
igh proportion of extended criteria donors, and the rou-
ine use of EuroCollins cold storage solution .1 NAC
administration in the early period after deceased donor
kidney transplantation reduced the frequency of DGF.
Although the strategy of antioxidant administration seems
to be reasonable, it warrants further investigation in other
and larger populations.
In conclusion, our study suggested that attenuation of
oxidative stress by NAC administration to recipients of
deceased donor renal transplant promoted faster and sus-
tained recovery of allograft function.
PROTECTIVE EFFECT OF N-ACETYLCYSTEINE 1447Fig 2. Mean  standard error of
the mean of serum creatinine
from deceased kidney transplant
recipients. The table shows a
comparison of serum creatinine
(mean  standard deviation)
between groups. PO, postopera-
tive day; NAC, N-acetylcysteine;
ANOVA, analysis of variance.Fig 3. Mean  standard error of
the mean of estimated MDRD
clearance from deceased kidney
transplant recipients. The table
shows a comparison of the esti-
mated MDRD clearance (mean 
standard deviation) between
groups. PO, postoperative day;
NAC, N-acetylcysteine; ANOVA,
analysis of variance; MDRD.
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